Matthew R. Henn - 27 Apr 2023 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role
Chief Scientific Officer and EVP
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn
Issuer symbol
MCRB
Transactions as of
27 Apr 2023
Net transactions value
$0
Form type
4
Filing time
01 May 2023, 16:41:28 UTC
Previous filing
07 Feb 2023
Next filing
31 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MCRB Stock Option (Right to Buy) Award $0 +35,000 +100% $0.000000 70,000 27 Apr 2023 Common Stock 35,000 $10.84 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. The option vested and became exercisable in two equal installments upon the satisfaction of certain performance criteria. On April 27, 2023, the Issuer's Board of Directors determined that the performance criteria for the second installment were met, resulting in vesting of the option as to 35,000 shares.

Remarks:

Chief Scientific Officer and EVP